Tuesday, November 27, 2018 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with advanced solid tumors, including lung cancer, that have a neurotrophic [...]